Daniel Bednarik, PhD

Interim Chief Science Officer

Dan brings more than 30 years of experience in molecular engineering, protein design, virology, and translational oncology research. His career has focused on advancing therapeutic platforms that bridge fundamental science and clinical applications. Dan has held C-level, senior scientific, and advisory roles in both academic and industry settings, contributing to programs spanning oncology, immunology, and viral pathogenesis.

At Lumigen, Dan leads scientific strategy and platform innovation, guiding the development of antibody-nanoparticle conjugates designed to target aggressive solid tumors. He is known for integrating deep scientific insight with practical development expertise to accelerate translation from concept to clinic.

Dan holds a PhD in Biochemistry from the Temple University School of Medicine and completed his postdoctoral research at The Johns Hopkins University Oncology Center in collaboration with Dana-Farber at Harvard University.